ViaCyte attracts crossover investors for $80M series D

ViaCyte Inc. (San Diego, Calif.) announced an $80 million tranched series D round to fund development of its Type I diabetes stem cell therapies.

ViaCyte President and CEO Paul

Read the full 281 word article

How to gain access

Continue reading with a
two-week free trial.